


Appl. No. 10/030,735
Amdt. dated June 24, 2005
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1644

PATENT

Amendments to the Specification:

Please replace the paragraph on page 16, lines 22-32, with the following amended paragraph:

The present invention generally provides peptides, comprising the sequence



wherein ~~X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; the X₁-X₂-X₃-X₄ sequence is selected from the group consisting of~~

N-V-R-V, N-V-R-I, N-V-R-L, N-V-R-F (SEQ ID NOS: 55-57 & 51),
N-V-K-V, N-V-K-I, N-V-K-L, N-V-K-F (SEQ ID NOS: 58-61),
N-I-R-V, N-I-R-I, N-I-R-L, N-I-R-F (SEQ ID NOS: 62-65),
N-I-K-V, N-I-K-I, N-I-K-L, N-I-K-F (SEQ ID NOS: 66-69),
N-L-R-V, N-L-R-I, N-L-R-L, N-L-R-F (SEQ ID NOS: 70-73),
N-L-K-V, N-L-K-I, N-L-K-L, N-L-K-F (SEQ ID NOS: 74-77),
Q-V-R-V, Q-V-R-I, Q-V-R-L, Q-V-R-F (SEQ ID NOS: 78-80 & 53),
Q-V-K-V, Q-V-K-I, Q-V-K-L, Q-V-K-F (SEQ ID NOS: 81-83),
Q-I-R-V, Q-I-R-I, Q-I-R-L, Q-I-R-F (SEQ ID NOS: 84-87),
Q-I-K-V, Q-I-K-I, Q-I-K-L, Q-I-K-F (SEQ ID NOS: 88-91),
Q-L-R-V, Q-L-R-I, Q-L-R-L, Q-L-R-F (SEQ ID NOS: 92-95),
Q-L-K-V, Q-L-K-I, Q-L-K-L, Q-L-K-F (SEQ ID NOS: 96-99),
D-V-R-V, D-V-R-I, D-V-R-L, D-V-R-F (SEQ ID NOS: 100-102 & 54),
D-V-K-V, D-V-K-I, D-V-K-L, D-V-K-F (SEQ ID NOS: 103-106),
D-I-R-V, D-I-R-I, D-I-R-L, D-I-R-F (SEQ ID NOS: 107-110),

Appl. No. 10/030,735

PATENT

Amdt. dated June 24, 2005

Amendment under 37 CFR 1.116 Expedited Procedure

Examining Group 1644

D-I-K-V, D-I-K-I, D-I-K-L, D-I-K-F (SEQ ID NOS: 111-114),D-L-R-V, D-L-R-I, D-L-R-L, D-L-R-F (SEQ ID NOS: 115-118),D-L-K-V, D-L-K-I, D-L-K-L, D-L-K-F (SEQ ID NOS: 119-122),S-V-R-V, S-V-R-I, S-V-R-L, S-V-R-F (SEQ ID NOS: 123-125 & 52),S-V-K-V, S-V-K-I, S-V-K-L, S-V-K-F (SEQ ID NOS: 126-129),S-I-R-V, S-I-R-I, S-I-R-L, S-I-R-F (SEQ ID NOS: 130-133),S-I-K-V, S-I-K-I, S-I-K-L, S-I-K-F (SEQ ID NOS: 134-137),S-L-R-V, S-L-R-I, S-L-R-L, S-L-R-F (SEQ ID NOS: 138-141),S-L-K-V, S-L-K-I, S-L-K-L, S-L-K-F (SEQ ID NOS: 142-145);

R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. In one embodiment of the invention, peptides having the sequence FQGV LQNVR FVF (SEQ ID NO:6) or FRGCVRNLRLSR (SEQ ID NO:12) are specifically excluded. In one embodiment, the peptides contain from 4 to 12 amino acids, i.e., has a length of 4 to 12 amino acid residues. In one embodiment, the peptides comprise additional residues, e.g., typically up to a length of 15, 20, 25, or 40 residues that includes the core sequence (I).